Dezhan Healthcare Company Limited.

Dezhan Healthcare Co., Ltd. is a pharmaceutical company listed on the Shenzhen Stock Exchange since 1998. The company specializes in the research and development, production, and commercialization of both chemical and biological drugs. It operates through its subsidiary, Jialin Pharmaceutical, which focuses on therapeutics for cardiovascular and cerebrovascular conditions, including hypercholesterolemia, hypertension, arrhythmia, and angina pectoris. Dezhan Healthcare has established a diverse product portfolio, which includes notable drugs such as Atorvastatin Calcium Tablets (ALe®) and Amlodipine Besilate and Atorvastatin Calcium Tablets (NiLe®). Dezhan Healthcare has maintained a strong presence in the domestic lipid-modulating drug market for over two decades, leveraging its extensive clinical experience and robust trial data to validate the efficacy of its products. The company operates a self-sustaining R&D ecosystem supported by specialized research institutes and a dedicated team of professionals, driving innovation in drug development. Dezhan Healthcare's flagship products have set quality benchmarks in the industry, and the company is actively exploring new business areas, including biological peptides and medical services, while continuing to enhance its competitive advantages in cardiovascular therapeutics.

Dezhan Healthcare has been deeply rooted in the domestic lipid-modulating drug market for over two decades, developing a comprehensive portfolio of commercial and pipeline chemical/biologic products. Its flagship ALe®—China's first generic Lipitor—established the "ALe Quality" benchmark, achieving critical milestones: passing 2018 consistency evaluation (proving bioequivalence and clinical substitutability), entering the National Essential Medicines List, and inclusion in the 2020 Chinese Pharmacopoeia， followed by pioneering China's first domestic Amlodipine/Atorvastatin generic (2021), successful NiLe® commercialization (2022), and NiLe®'s 2023 selection in China's 8th National Volume-Based Procurement (VBP). The company maintains market leadership through superior product quality, brand recognition, technical expertise, and manufacturing capabilities—forging distinctive competitive advantages in cardiovascular therapeutics. (1)Industry Experience Advantage Dezhan Healthcare has long maintained a deep presence in the cardiovascular and cerebrovascular disease therapeutic area, Jialin Pharmaceutical's pioneering development of ALe®—China's first generic Lipitor—which has been commercially available for over two decades. Extensive clinical experience across physician and patient populations, supported by robust trial data, has validated ALe®'s consistent therapeutic efficacy and quality standards, earning broad market acceptance. This established track record has cultivated a substantial, stable patient base in the lipid-lowering market, where long-term treatment needs drive high adherence. (2)Technological Research and Development Advantages Dezhan Healthcare operates a self-sustaining R&D ecosystem featuring four specialized pharmaceutical research institutes—Jialin Pharmaceutical Biotechnology Institute, Honghui New Medicine, Hantai Biological Research Institute, and Deyi Pharmaceutical—complemented by an Academician Workstation and Postdoctoral Research Station. The 200-member R&D team (representing 20% of total workforce) comprises advanced-degree professionals with deep industry expertise, driving both product optimization and novel drug development under leadership by overseas-trained pharmaceutical scientists. Anchored in the principle of "Innovating Quality Products, Leading Technological Frontiers," Dezhan prioritizes sustained R&D investment, achieving industrial-scale production of nine major drugs with nationally advanced manufacturing technologies. As one of the main contributing units to the project "Establishment and Application of Key Technology System for Crystal Forms of Chemical Drugs" (Project No.: J-235-2-01), Jialin Pharmaceutical jointly won the Second Prize of the National Science and Technology Progress Award. The company has developed unique core process technologies in the production of its main products such as Atorvastatin Calcium and Trimetazidine Hydrochloride. Dezhan leverages strategic partnerships with elite institutions including Chinese Academy of Medical Sciences, Capital Medical University, Sun Yat-sen University, and Shenyang Pharmaceutical University, accelerating cutting-edge research and talent cultivation. Sustained collaboration with CAE Academician Yang Baofeng further strengthens R&D capabilities while optimizing innovation pipeline efficiency. (3)Product Quality Advantage Jialin Pharmaceutical's flagship ALe®—China's first generic version of Pfizer's blockbuster lipid-lowering drug Lipitor®—combines significant brand equity with market leadership, delivering price competitiveness against imports while setting the domestic quality benchmark as the inaugural atorvastatin product to pass China's NMPA consistency evaluation. As approved drafting unit for national atorvastatin quality standards, Jialin has driven industry standardization through its CFDA-endorsed revisions to calcium and tablet specifications, simultaneously strengthening core competencies while providing high-quality therapeutics. Anchored in the principle that product safety and quality form the bedrock of operations, Dezhan Healthcare maintains internationally GMP-certified production lines—ensuring rigorous quality control that achieves 100% market surveillance sampling compliance for consecutive years. (4)Brand Advantage Dezhan Healthcare has consistently built its corporate and product brand image on the foundation of quality, continuously strengthening brand development and implementing brand and quality upgrading initiatives. Committed to actively fulfilling social responsibilities, the company remains dedicated to providing patients worldwide with exceptional medicines and services as our core corporate value. Jialin Pharmaceutical has cultivated a strong reputation in the industry for brands like "ALe®" and "NiLe®," built upon its comprehensive quality control system, uncompromising product quality, and proven therapeutic efficacy. Core brand attributes such as "Quality" and "Safety" resonate deeply with healthcare professionals and patients alike. (5)Advantages of the Management Team Dezhan Healthcare’s senior management team possesses extensive expertise in pharmaceutical production, marketing, and management, bringing advanced managerial concepts and sophisticated marketing strategies. Through prioritized talent acquisition, cultivation, and knowledge capital development, the company has built sustainable core competencies—culminating in a competitive advantage through its multidisciplinary core team of executive leadership, technical specialists, and commercial professionals.